Eli Lilly (LLY) Tax Provisions (2009 - 2026)

Eli Lilly has reported Tax Provisions for 18 years, with the latest figure at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 108.61% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $5.8 billion (up 134.51% YoY), and the FY2025 full-year result was $5.1 billion, up 143.59% from the prior year.
• Tax Provisions for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
• The five-year high for Tax Provisions was $1.6 billion in Q3 2025, with the low at $113.8 million in Q3 2022.
• Historically, Tax Provisions has averaged $618.3 million across 5 years, with a median of $484.6 million in 2023.
• Annual changes were most pronounced in 2022 — Tax Provisions tumbled 32.06% — and 2023, when it soared 325.83%.
• Eli Lilly's Tax Provisions stood at $158.7 million in 2022, then soared by 100.95% to $318.9 million in 2023, then surged by 97.08% to $628.5 million in 2024, then jumped by 159.11% to $1.6 billion in 2025, then declined by 10.72% to $1.5 billion in 2026.
• The last three Tax Provisions figures came in at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.